Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Epizyme Inc (NASDAQ:EPZM)

10.42
Delayed Data
As of Apr 29
 -0.64 / -5.79%
Today’s Change
8.27
Today|||52-Week Range
28.48
-34.96%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$596.2M

Company Description

Epizyme, Inc. operates as a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative personalized therapeutics for patients with genetically defined cancers. It engages in the creation of small molecule inhibitors of class of enzymes known as histone methyltransferases. The company was founded by H. Robert Horvitz and Yi Zhang on November 1, 2007 and is headquartered in Cambridge, MA.

Contact Information

Epizyme, Inc.
400 Technology Square
Cambridge Massachusetts 02139
P:(617) 229-5872
Investor Relations:
(617) 500-0712

Employees

Shareholders

Other institutional5.15%
Mutual fund holders41.67%
Individual stakeholders38.29%

Top Executives

Robert B. BazemorePresident, Chief Executive Officer & Director
Andrew E. SingerCFO, Treasurer & EVP-Finance & Administration
Robert A. CopelandChief Scientific Officer & President-Research
Tai-Ching HoChief Medical Officer
Robert J. GouldDirector